Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A two-stage phase I study to assess safety and efficacy of a live microbial biotherapeutic (SVT-1C469) as monotherapy for the treatment of Helicobacter pylori infection in otherwise healthy adults.

Next Previous
Trial Profile

A two-stage phase I study to assess safety and efficacy of a live microbial biotherapeutic (SVT-1C469) as monotherapy for the treatment of Helicobacter pylori infection in otherwise healthy adults.

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Jun 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SVT 1C469 (Primary)
  • Indications Helicobacter pylori infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Servatus Biopharmaceuticals

Most Recent Events

  • 23 Nov 2020 According to a Servatus Biopharmaceuticals media release, first patient has been dosed in this study.
  • 23 Nov 2020 Status changed from not yet recruiting to recruiting, according to a Servatus Biopharmaceuticals media release.
  • 23 Sep 2020 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top